Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Gerdts

Showing results (131-140 of 134) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 134 results.
Med (New York, N.Y.)|April 19, 2022
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variantsArinjay Banerjee, Jocelyne Lew, Andrea Kroeker, et al.
Vaccine|September 16, 2025
Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trialGlenn Hamonic, Elodie Pastural, Supriya Arora, et al.
Vaccine|May 20, 2024
Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernRavendra Garg, Qiang Liu, Jill Van Kessel, et al.
Vaccine|March 18, 2025
Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024Radhika Gharpure, Carolin Vegvari, Alemseged Abdissa, et al.
Pageof 14

Showing results (131-140 of 134) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 134 results.
Med (New York, N.Y.)|April 19, 2022
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variantsArinjay Banerjee, Jocelyne Lew, Andrea Kroeker, et al.
Vaccine|September 16, 2025
Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trialGlenn Hamonic, Elodie Pastural, Supriya Arora, et al.
Vaccine|May 20, 2024
Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernRavendra Garg, Qiang Liu, Jill Van Kessel, et al.
Vaccine|March 18, 2025
Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024Radhika Gharpure, Carolin Vegvari, Alemseged Abdissa, et al.
Pageof 14